AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NYSE:AZN
- CUSIP: N/A
- Web: www.astrazeneca.com
- Market Cap: $88.77949 billion
- Outstanding Shares: 2,532,000,000
- 50 Day Moving Avg: $33.53
- 200 Day Moving Avg: $30.13
- 52 Week Range: $25.55 - $35.33
Sales & Book Value:
- Trailing P/E Ratio: 26.33
- Foreward P/E Ratio: 18.60
- P/E Growth: 2.60
- Annual Revenue: $22.29 billion
- Price / Sales: 3.99
- Book Value: $5.13 per share
- Price / Book: 6.85
- Annual Dividend: $1.37
- Dividend Yield: 3.9%
- EBIDTA: $5.84 billion
- Net Margins: 15.21%
- Return on Equity: 35.65%
- Return on Assets: 8.77%
- Debt-to-Equity Ratio: 0.99%
- Current Ratio: 0.75%
- Quick Ratio: 0.58%
- Average Volume: 4.13 million shs.
- Beta: 0.81
- Short Ratio: 6.39
Frequently Asked Questions for Astrazeneca PLC (NYSE:AZN)
What is Astrazeneca PLC's stock symbol?
Astrazeneca PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."
How often does Astrazeneca PLC pay dividends? What is the dividend yield for Astrazeneca PLC?
Astrazeneca PLC announced a semiannual dividend on Friday, February 3rd. Investors of record on Friday, February 17th will be given a dividend of $0.95 per share on Monday, March 20th. This represents a yield of 6.81%. The ex-dividend date is Wednesday, February 15th. View Astrazeneca PLC's Dividend History.
When did Astrazeneca PLC's stock split? How did Astrazeneca PLC's stock split work?
Shares of Astrazeneca PLC split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of Astrazeneca PLC stock prior to the split would have 200 shares after the split.
How were Astrazeneca PLC's earnings last quarter?
Astrazeneca PLC (NYSE:AZN) announced its earnings results on Thursday, April, 27th. The company reported $0.99 EPS for the quarter, topping the Zacks' consensus estimate of $0.38 by $0.61. The company had revenue of $5.41 billion for the quarter, compared to the consensus estimate of $5.40 billion. Astrazeneca PLC had a return on equity of 35.65% and a net margin of 15.21%. The business's revenue was down 11.6% compared to the same quarter last year. During the same period last year, the firm posted $0.95 EPS. View Astrazeneca PLC's Earnings History.
Where is Astrazeneca PLC's stock going? Where will Astrazeneca PLC's stock price be in 2017?
19 brokers have issued 1-year target prices for Astrazeneca PLC's stock. Their forecasts range from $36.00 to $41.37. On average, they expect Astrazeneca PLC's stock price to reach $38.46 in the next year. View Analyst Ratings for Astrazeneca PLC.
Are investors shorting Astrazeneca PLC?
Astrazeneca PLC saw a decline in short interest in May. As of May 15th, there was short interest totalling 27,947,608 shares, a decline of 10.2% from the April 28th total of 31,107,207 shares. Based on an average daily volume of 4,927,299 shares, the days-to-cover ratio is presently 5.7 days.
Who are some of Astrazeneca PLC's key competitors?
Some companies that are related to Astrazeneca PLC include Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), GlaxoSmithKline plc (GSK), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Catalent (CTLT), Akorn (AKRX), Opko Health (OPK) and Hikma Pharmaceuticals Plc (HIK).
Who are Astrazeneca PLC's key executives?
Astrazeneca PLC's management team includes the folowing people:
- Pascal Soriot, Executive Director and Chief Executive Officer
- Marc Dunoyer, Executive Director, Chief Financial Officer
- Fiona Cicconi, Executive Vice-President, Human Resources
- Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
- Pam P. Cheng, Executive Vice President - Operations and Information Technology
- Ruud Dobber, Executive Vice President, North America
- Bahija Jallal Ph.D., Executive Vice President, MedImmune
- Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
- Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
- Leon Wang, Executive Vice President - Asia Pacific
Who owns Astrazeneca PLC stock?
Astrazeneca PLC's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (0.00%), Bank of America Corp DE (1.81%), Primecap Management Co. CA (0.00%), Epoch Investment Partners Inc. (0.00%), BlackRock Inc. (0.00%) and Schafer Cullen Capital Management Inc. (0.00%). View Institutional Ownership Trends for Astrazeneca PLC.
Who sold Astrazeneca PLC stock? Who is selling Astrazeneca PLC stock?
Astrazeneca PLC's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., FMR LLC, Credit Suisse AG, Sivik Global Healthcare LLC, Sensato Investors LLC, Epoch Investment Partners Inc., Cullen Capital Management LLC and Bluestein R H & Co.. View Insider Buying and Selling for Astrazeneca PLC.
Who bought Astrazeneca PLC stock? Who is buying Astrazeneca PLC stock?
Astrazeneca PLC's stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Primecap Management Co. CA, BlackRock Inc., Wellington Management Group LLP, Acadian Asset Management LLC, Wells Fargo & Company MN, Karp Capital Management Corp and Global Financial Private Capital LLC. View Insider Buying and Selling for Astrazeneca PLC.
How do I buy Astrazeneca PLC stock?
Shares of Astrazeneca PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Astrazeneca PLC's stock price today?
MarketBeat Community Rating for Astrazeneca PLC (NYSE AZN)MarketBeat's community ratings are surveys of what our community members think about Astrazeneca PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Astrazeneca PLC stock can currently be purchased for approximately $35.15.
Consensus Ratings for Astrazeneca PLC (NYSE:AZN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 7 Hold Ratings, 10 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.42)|
|Consensus Price Target: ||$38.46 (9.41% upside)|
Analysts' Ratings History for Astrazeneca PLC (NYSE:AZN)
(Data available from 6/27/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/17/2017||Leerink Swann||Reiterated Rating||Outperform||$33.00 -> $36.00||Low|
|5/12/2017||Credit Suisse Group||Upgrade||Underperform -> Neutral||High|
|4/10/2017||Jefferies Group LLC||Reiterated Rating||Buy -> Hold||Low|
|4/7/2017||HSBC Holdings plc||Downgrade||Hold -> Reduce||Low|
|3/9/2017||Liberum Capital||Initiated Coverage||Buy -> Buy||Low|
|3/7/2017||Barclays PLC||Initiated Coverage||Overweight||N/A|
|3/6/2017||Cowen and Company||Reiterated Rating||Market Perform||N/A|
|2/21/2017||Berenberg Bank||Reiterated Rating||Buy||N/A|
|12/13/2016||J P Morgan Chase & Co||Reiterated Rating||Neutral||N/A|
|11/11/2016||Deutsche Bank AG||Reiterated Rating||Buy||N/A|
|11/11/2016||Beaufort Securities||Reiterated Rating||Hold||N/A|
|11/10/2016||Cantor Fitzgerald||Reiterated Rating||Buy||N/A|
|11/10/2016||Bank of America Corporation||Reiterated Rating||Buy||$41.37||N/A|
|11/10/2016||Shore Capital||Reiterated Rating||Hold||N/A|
|11/7/2016||Citigroup Inc.||Reiterated Rating||Buy||N/A|
|10/5/2016||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Sell||N/A|
|9/23/2016||Piper Jaffray Companies||Initiated Coverage||Overweight||N/A|
|9/13/2016||BNP Paribas||Downgrade||Outperform -> Neutral||N/A|
|8/29/2016||Argus||Upgrade||Hold -> Buy||$38.00||N/A|
|2/28/2016||Drexel Hamilton||Initiated Coverage||Buy||N/A|
|2/5/2016||Sanford C. Bernstein||Lower Price Target||$34.00 -> $32.00||N/A|
|1/26/2016||Oddo Securities||Upgrade||Neutral -> Top Pick||N/A|
|12/30/2015||Morgan Stanley||Reiterated Rating||Buy||N/A|
|11/2/2015||Nordea Equity Research||Downgrade||Buy -> Hold||N/A|
|9/18/2015||Bryan, Garnier & Co||Upgrade||Neutral -> Buy||N/A|
|7/31/2015||S&P Equity Research||Upgrade||Buy||$38.00||N/A|
|7/31/2015||Swedbank||Upgrade||Neutral -> Buy||N/A|
Earnings History for Astrazeneca PLC (NYSE:AZN)Earnings History by Quarter for Astrazeneca PLC (NYSE AZN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/27/2017||3/31/2017||$0.38||$0.99||$5.40 billion||$5.41 billion||View||N/A|
|2/2/2017||Q416||$0.51||$1.21||$5.43 billion||$5.59 billion||View||Listen|
|11/10/2016||Q316||$0.48||$1.32||$5.95 billion||$5.70 billion||View||N/A|
|7/28/2016||Q216||$0.76||$0.83||$5.56 billion||$5.60 billion||View||Listen|
|4/29/2016||Q1||$0.60||$0.51||$5.96 billion||$6.12 billion||View||Listen|
|2/4/2016||Q415||$0.88||$0.94||$6.27 billion||$6.40 billion||View||N/A|
|11/5/2015||Q315||$0.51||$1.03||$5.90 billion||$5.85 billion||View||N/A|
|7/30/2015||Q2||$0.52||$1.21||$6.02 billion||$5.84 billion||View||Listen|
|4/24/2015||Q1||$1.07||$1.08||$5.87 billion||$6.06 billion||View||N/A|
|2/5/2015||Q314||$0.85||$0.76||$6.68 billion||$6.68 billion||View||N/A|
|11/6/2014||Q3||$1.04||$1.05||$6.44 billion||$6.54 billion||View||N/A|
|7/31/2014||Q214||$1.09||$1.30||$6.24 billion||$6.45 billion||View||N/A|
|4/29/2014||Q114||$1.23||$1.17||$6.32 billion||$6.42 billion||View||N/A|
|2/6/2014||Q413||$1.22||$1.23||$6.91 billion||$3.84 billion||View||N/A|
|10/31/2013||Q313||$1.27||$1.21||$6.45 billion||$6.25 billion||View||N/A|
|8/1/2013||Q213||$1.16||$1.20||$6.24 billion||$6.23 billion||View||N/A|
|4/25/2013||$1.36||$1.41||$6.54 billion||$6.39 billion||View||N/A|
|1/31/2013||Q412||$1.37||$1.56||$7.17 billion||$7.28 billion||View||N/A|
Earnings Estimates for Astrazeneca PLC (NYSE:AZN)
2017 EPS Consensus Estimate: $1.74
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Astrazeneca PLC (NYSE:AZN)
|Most Recent Dividend:||3/20/2017|
|Dividend Growth:||-21.20% (3 Year Average)|
|Payout Ratio:||51.31% (Trailing 12 Months of Earnings) |
74.05% (Based on This Year's Estimates)
72.49% (Based on Next Year's Estimates)
Dividend History by Quarter for Astrazeneca PLC (NYSE AZN)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Astrazeneca PLC (NYSE:AZN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Astrazeneca PLC (NYSE:AZN)
Latest Headlines for Astrazeneca PLC (NYSE:AZN)
Astrazeneca PLC (AZN) Chart for Tuesday, June, 27, 2017